Literature DB >> 1359396

Coexisting beta 1- and atypical beta-adrenergic receptors cause redundant increases in cyclic AMP in human neuroblastoma cells.

T A Esbenshade1, C Han, T L Theroux, J G Granneman, K P Minneman.   

Abstract

In SK-N-MC human neuroblastoma cells, the cAMP response to 10 nM isoproterenol (ISO) is mediated primarily by beta 1-adrenergic receptors. However, responses to higher concentrations of ISO (100-1000 nM) were only weakly blocked by beta 1- and beta 2-selective antagonists. When beta 1 receptors were blocked with 10 microM CGP 20712A, catecholamines still maximally activated cAMP accumulation, with only small decreases in potency. In the presence of CGP 20712A, beta blockers inhibited the response to ISO stereoselectively but with relatively low potencies. Pindolol derivatives were partial agonists with low potencies, and the atypical agonist BRL 37344 was a partial agonist with an intermediate potency. All binding sites in these cells labeled by 125I-cyanopindolol were of the beta 1 subtype. Nuclease protection assays indicated that SK-N-MC cells contain mRNA for both the human beta 1- and beta 3-adrenergic receptors, with the beta 3 subtype mRNA being expressed 25-50% more abundantly than that for the beta 1 subtype. Northern blot hybridizations showed the presence of two beta 3 mRNA transcripts of 3.1 and 2.4 kilobases. These results suggest that beta 1- and atypical beta-adrenergic receptors coexist in these cells and cause redundant increases in cAMP formation. Although molecular approaches suggest that the atypical subtype is the beta 3, the observed drug specificity differs from that reported for the expressed recombinant human beta 3 receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359396

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  5 in total

Review 1.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

2.  Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

3.  Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium.

Authors:  M Bardou; C Loustalot; J Cortijo; B Simon; E Naline; M Dumas; S Esteve; T Croci; P Chalon; R Frydman; P Sagot; L Manara; E J Morcillo; C Advenier
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor.

Authors:  N Blin; C Nahmias; M F Drumare; A D Strosberg
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

5.  Beta-adrenoceptor subtypes mediating the airways response to BRL 35135 in man.

Authors:  D M Newnham; C G Ingram; A Mackie; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.